How to compare which NPWT pump to buy? Check out this Medela vs Cobaltt Comparison sheet

npwt pump, medela npwt pump, wound pump, negative pressure wound therapy, cobaltt npwt
Medela Liberty NPWT PUMP vs Cobaltt NPWT pump system
Product Name Cobaltt NPWT Pump Medela Invia Liberty
Price $2780.00 > $4,000.00
Foam dressing Black Foam Dressing Green Foam Dressing
Portable YES YES
Financing options Capital purchase/Available for lease to own Capital purchase/rental
LCD screen YES YES
Therapy mode Continuous and Intermittent Continuous and Intermittent
Additional cost for canister tubing NO YES
Various canister options YES YES
Portable carrying case Yes Yes

 

Equinox support our dealer network and do not sell the end user, like our competitors.   We believe our dealers are our partners and provide support through a variety of offerings. In addition,  we provide black foam,  which is an industry standard, this saves our dealers time in educating their customers.

 

Have you tried the best NPWT rental company in the US

After seeing all the big changes going on the durable medical equipment market. The one that always stand out is MedcoAmerica from Louisiana. This company continue to grow even with all the changes on the Medicare/Medicaid changes in our domestic healthcare. The company specialize on Negative pressure wound therapy pumps, NeutroPhase wound cleansing and Black foam dressing. This company controls the wound care market in the south and taking a big chunk of market share from the market leader.

MedcoAmerica is one of the fastest growing npwt pump rental company in the US. They are looking for a distributors and partners across America. If interested, check out their website at www.medcoamerica.com.

 

MedcoAmerica NPWT Pump Rentals

Have you tried the best NPWT rental company in the US

After seeing all the big changes going on the durable medical equipment market. The one that always stand out is MedcoAmerica from Louisiana. This company continue to grow even with all the changes on the Medicare/Medicaid changes in our domestic healthcare. The company specialize on Negative pressure wound therapy pumps, NeutroPhase wound cleansing and Black foam dressing. This company controls the wound care market in the south and taking a big chunk of market share from the market leader.

MedcoAmerica is one of the fastest growing npwt pump rental company in the US. They are looking for a distributors and partners across America. If interested, check out their website at www.medcoamerica.com.

 

MedcoAmerica NPWT Pump Rentals

Have you tried the best NPWT rental company in the US

After seeing all the big changes going on the durable medical equipment market. The one that always stand out is MedcoAmerica from Louisiana. This company continue to grow even with all the changes on the Medicare/Medicaid changes in our domestic healthcare. The company specialize on Negative pressure wound therapy pumps, NeutroPhase wound cleansing and Black foam dressing. This company controls the wound care market in the south and taking a big chunk of market share from the market leader.

MedcoAmerica is one of the fastest growing npwt pump rental company in the US. They are looking for a distributors and partners across America. If interested, check out their website at www.medcoamerica.com.

 

MedcoAmerica NPWT Pump Rentals

The lightest and portable Cobaltt NPWT pump is now available in the US

I am glad to report that the newest, lightest, and portable Cobaltt negative pressure wound therapy pump is now available in the US. This pump was designed in Germany and by the looks of it its built for a durable use. This particular NPWT pump can be use in the Hospital, acute care, long term care, assisted living and home care setting. The pump comes with a easy to read LCD screen. Cobaltt npwt pump is designed with two npwt therapy modes, continuous and intermittent. Whether the physician prescribed a continuous pressure of 125mmHg or an intermittent of -125mmhg of high pressure for 5 minutes (adjustable) and -80mmHg low pressure for 2 minutes. The caregiver can adjust the pump with such ease.

I love how the pump actually comes with a portable bag for patient you are ambulatory. I see a lot of active patients that need NPWT therapy and they need to be stuck in their rooms while receiving the treatment. They can go out enjoy the world, go hang out with the family at a park, restaurant or wherever they wish to spend their day. The pump is good to go for 24 hours once its fully charge. Imagine, you don’t have to worry about charging the npwt pump while you are out doing your errands. But you only have to charge this Negative pressure wound therapy pump for four hours to be fully charge. Cobaltt also comes with two canister options, 300cc (for low exudate wounds) and 500cc for heavy exudate. In addition, Cobaltt also comes with a NPWT black foam dressing kits, which is a wound care market standard. Majority of the caregivers in healthcare facilities are familiar withe the black foam dressing change protocol which equates to faster implementation of this new NPWT pump in any facility. They already know how to use and put the dressing even without seeing it.

With the Smith and Nephew Renasys Recall happening as of June 2014, many durable medical equipment dealers and NPWT rental companies have been hit dramatically. They have patients that are currently on Renansys NPWT pump and they have to take them off and use a different npwt pump instead. Plus I am not sure if Medicare/Medicaid will continue to reimburse the facility if the renasys npwt pump is on recall. That would be a good question to ask right away. If you are a dealer and looking for a new npwt pump and needs it right away. Give the guys at Equinox Medical a call. They can help you go through this NPWT recall at this time or until Smith and Nephew fixes their problem. This recall and resolutions will usually takes about 120 to 240 days before you get an answer from the FDA after Smith and Nephew submits their 510K adjustments.

negative pressure wound therapy negative pressure wound therapy pump negative pressure wound therapy wound vacuum 300cc npwt pump canister cobaltt cobalt canister pic 3 for website

 

 

Former KCI executive now running another NPWT Pump Company

Spiracur Appoints Chris Fashek as Its New President and CEO

SUNNYVALE, CA, Jul 09, 2014 (Marketwired via COMTEX) — Spiracur, the developer of the only mechanically powered advanced wound care solution that delivers the proven efficacy of Negative Pressure Wound Therapy (NPWT), today announced the appointment of Chris Fashek as president and chief executive officer. With two decades of experience leading health care companies, Fashek will oversee execution of Spiracur’s development and growth strategies as it expands its global presence as a preferred provider of innovative wound healing technologies.

Prior to joining Spiracur, Fashek served as president and vice chairman of Kinetic Concepts, Inc. (KCI) USA, which is the leader in NPWT of the wound care industry. Before joining KCI, he managed businesses in the pharmaceutical and consumer product markets for Sterling Drug, a division of Eastman Kodak in the United States and internationally. Mr. Fashek currently serves as chairman of the Board of Directors for Spiracur, and director of the IDN Summit, the World Craniofacial Foundation, and other commercial and charitable boards. Fashek received his Masters in Business Administration from Fairleigh Dickinson University and a Bachelor of Arts from Upsala College.

“I am very excited to assume this new role at Spiracur at this time, as the company has significant elements in place for expanding its commercial success,” said Fashek. “Spiracur has the opportunity for sizeable growth due to a substantial increase in covered lives including Medicare reimbursement and positive coverage decisions from multiple private payors, as well as being added as an approved product in two of the largest U.S. GPOs. Not only is Spiracur extremely well positioned to enhance wound care treatment for patients who can benefit from NPWT, but this patient population is growing even larger as we announce new product offerings later this year, which expand our technology platform for broader usage,” continued Fashek.

Spiracur is credited with creating a new category of chronic and acute wound management solutions that combine the benefits of advanced wound care with non-powered NPWT. The SNaP(R) (Smart Negative Pressure(R)) System provides patients with a sophisticated, non-invasive NPWT system designed to promote wound healing, which weighs only 2.2 ounces and does not require batteries or electricity.

Several clinical studies have been published supporting the SNaP System as an effective alternative to electrically powered NPWT, including a comparative Randomized Controlled Trial (RCT) that also showed the small device makes a positive difference in patients’ quality of life. Recently, promising data from the multicenter RCT comparing the treatment of venous leg ulcers (VLU) using the mechanically powered SNaP System, to an electrically powered NPWT system, was presented at the Symposium on Advanced Wound Care (SAWC) Spring Conference in April.

According to Spiracur’s chief scientific officer, Kenton Fong, M.D., “This recent RCT data shows extremely promising results for the SNaP System when used to treat venous leg ulcers. Specifically, the data revealed that wounds treated with the SNaP System demonstrated greater improvement and a higher likelihood of complete wound closure than those treated with the electrically powered VAC system.”

About Spiracur Inc. Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford University Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The company’s ciSNaP(R) Closed Incision System with proprietary controlled tension relief is designed to improve healing of high-risk surgical incisions. Both devices have received 510(k) clearance from the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. Spiracur’s proprietary mechanically powered technology does not require batteries or electricity to operate. For more information, please visit http://spiracur.com .

Spiracur, Spiracur logo, SNaP, Smart Negative Pressure, and ciSNaP are registered trademarks of Spiracur Inc. VAC is a registered trademark of Kinetic Concepts, Inc.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2629258

KCI settles Wake Forest wound care patent spat for $280M

KCI settles Wake Forest wound care patent spat for $280M

July 1, 2014 by Brad Perriello

Kinetic Concepts Inc. agrees to a $280-million settlement of its long-running patent infringement war with Wake Forest University over negative-pressure wound therapy technology.

KCI settles Wake Forest wound care patent spat for $280M

UPDATED July 1, 2014, with comment from KCI.

Kinetic Concepts Inc. said it agreed to pay $280 million to settle a patent infringement lawsuit with Wake Forest University, putting their long-running war over negative-pressure wound therapy to rest.

KCI licensed the NPWT patents from Wake Forest in 1993, but stopped paying royalties in 2011 after a federal judge in 2010 ruled the patents invalid.

Sign up to get our free newsletters delivered straight to your inbox

A year later KCI and wound-care rival Smith & Nephew (FTSE:SN, NYSE:SNN), which had been tussling over the technology since Smith & Nephew’s 2007 acquisition of Blue Sky Medical Group, put their legal battle to rest as well.

Yesterday KCI said that it agreed to settle with Wake Forest via a series of payments covering retrospective royalties on the patents.

The deal calls for KCI to pay $80 million this month, another $85 million in June 2015, $85 million in June 2016 and a final $30 million payment in June 2017, according to a regulatory filing.

The Settlement Agreement includes a stipulated dismissal with prejudice of the lawsuits between KCI and Wake Forest, including the lawsuit that was previously scheduled to begin trial on July 28, 2014 in the U.S. District Court for the Western District of Texas, San Antonio Division.

“We are pleased to have resolved all negative pressure wound therapy patent litigation with Wake Forest. KCI pioneered the use of negative pressure wound therapy products when we launched our first V.A.C. Therapy System in 1994 and in so doing, improved the lives of millions of people. Today, KCI’s V.A.C. Therapy has been the treatment of choice for more than 8 million wounds worldwide and is the most effective therapy for accelerating wound healing,” KCI general counsel John Bibb said in prepared remarks.

Proposal to list surgical sutures, wound care products and disposable laparoscopic trocars and associated instruments

Proposal to list surgical sutures, wound care products and disposable laparoscopic trocars and associated instruments

Published By   /   July 9, 2014  /   No Comments

MIL OSI – Source: Pharmac – Press Release/Statement

Headline: Proposal to list surgical sutures, wound care products and disposable laparoscopic trocars and associated instruments

Proposal to list surgical sutures, wound care products and disposable laparoscopic trocars and associated instruments

8 July 2014

PHARMAC is seeking feedback on a proposal to list a range of surgical sutures, wound care products and disposable laparoscopic trocars and associated disposable instruments (“Medical Devices”) in Part III of Section H of the Pharmaceutical Schedule as a result of a provisional agreement (“Agreement”) with Covidien New Zealand Limited (“Covidien”).

In summary, this proposal would result in Covidien’s ranges of Medical Devices being available for DHBs to purchase at PHARMAC negotiated prices from 1 September 2014, subject to consultation and approval.

PHARMAC estimates that the proposal would offer at least $640,000 in savings per annum to those DHBs that currently purchase the Medical Devices, and could offer further significant savings should any other DHBs decide to purchase the Medical Devices.

DHBs may continue to choose to purchase other suppliers brands of medical devices.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 28 July 2014 to:

Maree Hodgson
Procurement Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: devices@pharmac.govt.nz

Fax:     04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal. Please contact us if you would like to discuss the timing of your submission outside this timeframe. Please note that extending the timeframe is likely to delay the potential savings to DHBs.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

Details of the proposal

Covidien’s range of Medical Devices would be listed in Part III of Section H of the Pharmaceutical Schedule from 1 September 2014.

The product range includes:

Sutures

  • Biosyn
  • Caprosyn
  • Dermalon
  • Flexon
  • Maxon
  • Maxon CV
  • Monosof
  • Novafil
  • Polysorb
  • Sofisilk
  • Stainless Steel
  • Surgidac
  • Surgilon
  • Surgipro
  • Surgipro II
  • Ticron
  • Velosorb
  • V-Loc
  • Umbilical tape
  • Suture Bolsters
  • Teflon Pledgets
  • Bone Wax

Wound care products

  • Curasorb
  • Curity Multitrauma
  • Excilon
  • Kendal AMD
  • Kendall Copa
  • Kendall Plus
  • Kerlix
  • Mothermates
  • Polyskin
  • Telfa
  • Vaseline dressings
  • Xeroform

Disposable laparoscopic devices

  • Dexide
  • Endo
  • FRED
  • Mini Step
  • Pediport
  • Poly
  • PLDS
  • Premium
  • Roticulator Endo
  • SILS
  • Step
  • Surgineedle
  • Surgisleeve
  • Surgiwand
  • Thoracoport
  • Roticulat
  • Versaport
  • Versaport V2
  • Versastep
  • Visiport

If the Agreement is approved by PHARMAC’s Board or its delegate, Covidien’s range of Medical Devices would be listed in Part III of Section H of the Pharmaceutical Schedule, which contains products with national agreements that DHBs are able to purchase under.

The Agreement includes terms for education services to be provided by Covidien to DHB personnel on appropriate use of its Medical Devices, which is to be provided at times as agreed with individual DHBs.

The exact product list, pricing and specific Agreement arrangements in the proposal have not been included in this consultation for brevity. The surgical suture and disposable laparoscopic medical device ranges both have a tiered pricing arrangement that could offer further savings to the Schedule listed pricing for increased individual DHB commitment. The details of this tiered pricing arrangement and commitment levels would remain confidential and would only be made available to Procurement Departments at DHBs to work through with their clinical teams. Some DHBs already qualify based on current usage of Covidien product for the second tier pricing offered and they will be notified individually.

For the Suture range the Agreement also allows for supplier managed inventory systems to be put in place for those DHBs who wish to utilise this service.

The range of Medical Devices would be listed in Part III of Section H of the Pharmaceutical Schedule. We propose that the Medical Devices would not be individually listed in the printed Section H of the Pharmaceutical Schedule, but rather a reference made in Part III of Section H to an electronic source available on our website in an Excel spreadsheet format, and a PDF document.

Background

In the May 2013 PHARMAC consultation, Surgical Sutures and Wound Care products were identified as 2 of the 11 categories PHARMAC would be working on as part of the phased plan for PHARMAC to progressively take on the management of hospital medical devices.

In August 2013 PHARMAC issued a registration of interest document, seeking proposals from suppliers for non-exclusive national agreements for wound care products. Following the closure of this request, we have been working with a number of suppliers in order to seek to reach an agreement with them, Covidien responded to this request.

In September 2013 a direct approach to the known suppliers in the New Zealand market, with comprehensive surgical suture ranges was made. This approach was in the form of a request for a submission to PHARMAC for a listing on the Pharmaceutical schedule and Covidien responded to this request.

Laparoscopic disposable trocars and associated instruments was not part of PHARMAC’s initial group of categories for medical devices consulted on in May 2013. The opportunity to list these medical devices was presented to PHARMAC following the initial consultation that identified the categories and significant saving opportunities for DHBs was offered. PHARMAC assessed the potential opportunity and determined it was substantial and would be worthwhile pursuing.

Following further consultation with; the sector as a whole, the Royal Australasian College of Surgeons specifically, and DHB Procurement teams, PHARMAC chose to pursue the opportunity offered in the disposable laparoscopic market. In November 2013 a direct approach to the known suppliers with comprehensive disposable laparoscopic device ranges in the New Zealand market was made and Covidien responded to this.

No reusable vs. disposable costing models have been undertaken on this range of medical devices for this process as PHARMAC is looking to obtain improved pricing on disposable products already in use in DHB’s, not advocating a change to disposable products. DHBs role in choosing the mix of disposable and reusable equipment they use would not be altered by this proposal.

The range of products available in all three categories would not be altered by this proposal and DHBs would continue to be able to choose which medical devices they purchase.

PODCAST: Chronic wound care offers insight into battling biofilms

PODCAST: Chronic wound care offers insight into battling biofilms


EXPERT ANALYSIS FROM THE SUMMIT IN AESTHETIC MEDICINE


DANA POINT, CALIF. – “Biofilms are ubiquitous,” said Dr. Robert Galiano, a plastic and reconstructive surgeon at Northwestern Memorial Hospital in Chicago.

“They [bacteria] hijack the body’s healing mechanisms, so instead of healing, … the body’s inflammatory cascade gets amplified to a degree where it actually becomes tissue damaging,” he said at the Summit in Aesthetic Medicine 2014.

Much of what we know about how bacteria communicate with one another to form biofilms comes from research into the prevention and treatment of chronic wounds. More research is needed, but greater understanding of how bacteria communicate with one another to prevent antimicrobial action may lead to new therapeutic targets that could benefit many medical specialties, he added.

Potential therapeutic targets range from coatings for wound dressings to protective barriers on stents and implants of all kinds to extend their durability. In this interview, Dr. Galiano discusses current treatment strategies to manage bacteria, which patients are at greatest risk, and future directions for biofilm prevention.

The summit was held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications. Dr. Galiano had no financial conflicts to disclose.

Equinox Medical, LLC newest NPWT Pump in the woundcare market

Equinox Medical Introduces Their Ultra Portable Cobaltt NPWT Pump System

Smithfield, RI-June 24, 2014 Equinox Medical, LLC, developer of negative pressure wound therapy (NPWT) foam dressings and NPWT pump systems, announced today that it will officially distribute the Cobaltt NPWT pump system. The Cobaltt NPWT pump is a light-weight, portable and versatile device indicated for patients who would benefit from the application of negative pressure.

The Cobaltt npwt pump system features a LCD screen control and user friendly interface functions. It is designed with a 300cc or 500cc canister, to handle moderate to heavy exudating wounds. The Cobaltt pump system was designed with the patient needs in mind, its ideal for patient who needs to be mobile or ambulatory. It weight about 3lbs and holds a 24 hour battery charge. Cobaltt NPWT pump

“The Cobaltt NPWT pump system will help patients return to their normal lifestyle, while receiving negative pressure in a compact portable unit,” says Gary Schear, Vice President of Sales from Equinox Medical. “The device’s portability allows patients to receive wound healing treatment inside of their own home while participating in normal daily activities. We are very confident that all our patients’ will improve their quality of life and all our caregivers will significantly enjoy the features on the Coballt’s innovative interface.”

The Cobaltt pump helps manage chronic, acute, traumatic, subacute and dehisced wound, partial-thickness burns, diabetic and pressure ulcers, flaps and grafts. The system can be utilized in acute hospital settings, wound clinic, nursing homes, and inside patient’s homes under supervision of a trained healthcare professional. The product will be available in the U.S in June 2014.

For more product information, please visit Learn More About Cobaltt NPWT pump system

 

About EquinoxO2 Medical, LLC

Equinoxo2 Medical, LLC, headquartered in Smithfield, RI is a privately held medical device company focused on the development of advanced wound healing technology. Equinox is dedicated to developing and designing innovative wound care products that are cost effective and delivers significant clinical outcomes. Our goal and strategy is to improve a patient’s quality of life. Our passion and dedication is to provide a better solution in repairing and healing the human body. For more information, please visit www.equinoxo2.com.

Media Contact

Gary Schear, Vice President of International and USA Sales

Telephone: 800-504-3150 Ext 104

Email: Gary@equinoxo2.com

Cobaltt NPWT Pump by Equinox Cobaltt NPWT Pump User InterfaceCobaltt NPWT Pump System by Equinox Medical Cobaltt NPWT Pump Canisters Cobaltt NPWT PUmp Canister